How Cloudbyz CTMS unified with CTFM and eTMF cuts site delays, budget drift, and R3 risk.
When clinical, financial, and document systems operate in isolation, every activation decision becomes a reconciliation exercise. Here is what that costs — and how a unified Salesforce-native platform changes the equation.
Disconnected CTMS, finance, and eTMF stacks create three separate versions of the same trial. In CTMS, teams see study, country, and site milestones — feasibility, selection, submissions, approvals, contracts, startup visits, activation, enrollment, monitoring, and close-out. In a separate finance tool — or in spreadsheets — Finance builds and updates trial budgets, investigator grants, and accrual models. eTMF portals, often implemented by different vendors or CROs, hold the documents regulators will eventually inspect.
Each system is accurate inside its own boundary. The problem for Clinical Operations leaders is everything that happens in between.
|
In the US and across EU member states, site activation dates slip because a country package sits in legal but CTMS only shows "submission complete." Startup fees go out based on contract signature dates while eTMF still lacks signed investigator agreements or local approvals. Sites appear green in CTMS because key milestones are ticked, yet essential records arrive weeks late or with incomplete metadata. |
In quarterly portfolio reviews, Clinical Operations is held accountable for enrollment curves that depend on sites Finance believes are funded and TMF teams believe are still incomplete. Those gaps are not just operational irritants.
Cloudbyz is designed to close that loop — not layer another reporting tool on top. As the only 100% Salesforce-native unified eClinical platform, Cloudbyz CTMS, CTFM, and eTMF all run on the same Salesforce data, security, and audit model. That means one definition of a study, country, site, subject, and visit, and one audit spine that records how activation, budgets, and records evolve.
When activation data, financial rules, and TMF records live in separate systems, the best your teams can do is reconcile. Clinical Operations shares spreadsheets of red and amber sites. Finance brings pivot tables showing budget burn by geography and vendor. TMF leads share reports of missing or late artifacts across zones. Each group is working hard — and yet no one can answer, in one place, why activation is slipping in specific EU member states or US regions.
On Cloudbyz, CTMS, CTFM, and eTMF are three faces of the same Salesforce-native platform. That unification changes how you design workflows.
In CTMS, country and site activation paths become explicit, object-based workflows. Each step — regulatory package submitted, authority approval, ethics/IRB approval, contract sent, contract signed, essential-doc packages complete — is a tracked event with timestamps, owners, and dependencies. CTFM sits directly on top of those same records: global and country budgets, investigator grants, and rate cards are defined against the exact sites and visit schedules your CTMS team uses. Startup, close-out, and milestone fees are linked to CTMS events. Accrual rules are expressed in terms CTMS understands — planned and actual visits, screen failures, optional procedures by subject and by site.
eTMF attaches essential records and rich metadata to the same studies, countries, and sites. Ethics approvals, authority letters, contracts and amendments, CVs, training records, and monitoring reports are not just files in folders — they are linked artifacts with status and versioning that your CTMS views can interpret.
|
A site that is "green" in CTMS for activation but "red" in eTMF for missing local approvals will never look healthy in the portfolio view. A country whose startup spend has been consumed in CTFM but whose sites have not reached first-patient-in will surface as a concrete, explainable risk. |
For VPs, Directors, and Heads of Clinical Operations, this means the weekly startup call can move away from reciting lists of late sites. Instead, your teams can focus on three questions: which part of each activation path is stuck, what contract or grant dependency is blocking payment, and which essential records are lagging behind.
Once you close the architecture gap, you can finally design risk and oversight on top of it. ICH E6(R3), adopted at Step 4 on 6 January 2025, reframes oversight around risk-proportionate quality management and planned review of trial-specific data and metadata, including audit trails. EMA's guideline on computerised systems and electronic data in clinical trials expects sponsors to explain how their systems behave across the data lifecycle.
On a fragmented stack, activation KRIs, budget controls, and TMF oversight are defined in different tools and stitched together for slide decks. On Cloudbyz, they can be defined once and reused, because they all act on the same records.
When any of those KRIs breach thresholds, Cloudbyz CTMS can automatically create tasks, escalate to country leads, or recommend monitoring or contracting interventions. CTFM can lock further payments until issues are resolved. eTMF can prioritize AI-assisted classification and QC for the affected records. All of those actions are captured by Cloudbyz Audit Trail & e-Signature as ALCOA+-aligned events.
If inspectors or internal QA ask why a site in Spain or an academic centre in the US was allowed to activate — or why additional payments were released — you can walk from KRIs to decisions to documentation in one system.
|
For Biotech and CRO leaders running trials across the US and Europe, this unification is what turns ICH E6(R3) from an abstract standard into a daily operating principle. Activation, spend, and essential records move together, on a spine you can inspect — and defend. |
Cloudbyz is the only 100% Salesforce-native unified eClinical platform purpose-built for pharma, biotech, and CRO organizations. This article is part of the Cloudbyz Clinical Operations thought leadership series.